Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Plaque psoriasis

Plaque psoriasis

Part of Psoriasis

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Plaque psoriasis

202 trials tracked for Plaque psoriasis: 109 in phase 3 or 4 and 44 with published results. The most-cited published study has 569 citations.

202Trials tracked
109Phase 3 & 4
0Recruiting
44With published results
Phase distribution
Phase 4 35 Phase 3 74 Phase 2 71 Phase 1 7 Other / NA 15
  1. Phase 3 A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) Completed · 569 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) Completed · 568 cited
  3. Phase 3 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Completed · 199 cited
  4. Phase 3 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Completed · 199 cited
  5. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
Show 44 more trials
  1. Phase 3 A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate Completed · 153 cited
  2. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 131 cited
  3. Phase 4 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 122 cited
  4. Phase 3 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Completed · 119 cited
  5. Phase 3 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Completed · 119 cited
  6. Phase 3 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris Completed · 114 cited
  7. Phase 4 Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis Completed · 98 cited
  8. Phase 3 LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris Completed · 97 cited
  9. Phase 3 Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Completed · 76 cited
  10. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 67 cited
  11. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 67 cited
  12. Phase 3 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 67 cited
  13. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 67 cited
  14. Phase 3 Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed · 51 cited
  15. Phase 3 Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Completed · 46 cited
  16. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 46 cited
  17. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Completed · 43 cited
  18. Phase 3 Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis Completed · 42 cited
  19. Phase 4 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed · 41 cited
  20. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 40 cited
  21. Phase 3 This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream Completed · 28 cited
  22. Phase 3 A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream Completed · 27 cited
  23. Phase 3 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Completed · 18 cited
  24. Phase 3 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy Completed · 13 cited
  25. Phase 3 Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) Completed · 13 cited
  26. Phase 4 Pain Outcomes Following Intralesional Corticosteroid Injections Completed · 9 cited
  27. Phase 3 LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Completed · 9 cited
  28. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis Completed · 8 cited
  29. Phase 4 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast Completed · 7 cited
  30. Phase 3 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Completed · 5 cited
  31. Phase 3 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab Completed · 4 cited
  32. Phase 3 Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity Completed · 3 cited
  33. Phase 4 Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis Completed · 2 cited
  34. Phase 4 Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients Completed · 2 cited
  35. Phase 3 A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis Completed · 1 cited
  36. Phase 4 Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis Completed
  37. Phase 3 A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) Completed
  38. Phase 3 A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310) Completed
  39. Phase 4 Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis Completed
  40. Phase 4 Plaque Psoriasis Study in Pediatric Subjects Completed
  41. Phase 4 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Completed
  42. Phase 4 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed
  43. Phase 4 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed
  44. Phase 4 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis Completed

Showing the 50 most-cited and recently-updated of 202 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Plaque psoriasis: what the trials found

Several biologics demonstrate significant efficacy in treating plaque psoriasis. Bimekizumab achieved a PASI90 response rate of 94.0% and an IGA 0/1 response rate of 92.0% at week 16 1. Ixekizumab demonstrated high rates of PASI 90 (58.5%) and PASI 75 (22.9%) in a large-scale study, with significant superiority over the comparator in both metrics 7. Additionally, Ixekizumab showed an 86.0% PASI-75 response rate at week 12 in patients with no active psoriatic arthritis 13.

JNJ-77242113 demonstrated consistent improvements across multiple trials; notably, it achieved a PASI-75 of 58.1% to 78.6% and PASI-90 rates ranging from 25.6% to 59.5% at week 16 [3, 5]. Secukinumab showed significant PASI 90 results at week 52 (70 participants vs 32 in the comparator) 14, and was associated with high DLQI 0/1 response rates of approximately 61.7% to 74.7% at both weeks 16 and 52 9. Tildrakizumab showed sustained PASI scores through week 96 6.

Etanercept achieved a PASI-75 response of 41.6% by week 12, with PASI-50 rates reaching up to 74.0% during the observation period 11. Apremilast demonstrated significant improvements in nail psoriasis, including a mean 64.1% reduction in mNAPSI at week 36 and a 50.42% reduction in patient-reported nail pain by week 52 19.

Various topical and localized treatments were evaluated: DFD-01 (betamethasone dipropionate) spray resulted in reductions in Investigator's Global Assessment grade (-0.8) and body surface area involvement (-1.3) 21. Lac-Hydrin lotion combined with UItravate ointment showed significant improvements in physical global assessment and signs of psoriasis, atrophy, or telangiectasis 12.

Recent results — preliminary, needs further review

  • Total coumarin (TC) cream was evaluated for PASI 75 improvement (9% vs 1%) and DLQI scores 4.

For the clinician treating this condition

  • Bimekizumab, Ixekizumab, and JNJ-77242113 are established options with high PASI-90 and PASI-75 response rates.
  • Secukinumab provides consistent improvement in both clinical scores (PASI) and patient-reported quality of life (DLQI).
  • Apremilast is an established option for managing nail psoriasis, showing significant reduction in mNAPSI and reported pain.

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27
Dermatology Meta-analysis
Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27 Icotrokinra Shows Promise for Moderate to Severe Plaque Psoriasis
This meta-analysis of icotrokinra for moderate-to-severe plaque psoriasis in adolescents and adults found a risk ratio of 7.27 for Investiga…
A new treatment called icotrokinra shows significant skin clearance and improved scores for adults and teens with moderate to severe plaque …
Oct 27, 2026
Comparative Efficacy and Safety of Ustekinumab Biosimilars versus Reference Products in Plaque Psoriasis
Dermatology Meta-analysis
Comparative Efficacy and Safety of Ustekinumab Biosimilars versus Reference Products in Plaque Psoriasis Ustekinumab biosimilars show similar results to the original drug
Meta-analysis confirms that ustekinumab biosimilars demonstrate comparable efficacy and safety profiles to the reference product for moderat…
New data shows that biosimilar versions of the drug ustekinumab work just as well as the original for people with moderate to severe plaque …
Oct 1, 2026
Guselkumab achieves 88.8% IGA 0/1 at week 16 in Chinese patients with plaque psoriasis
Dermatology RCT
Guselkumab achieves 88.8% IGA 0/1 at week 16 in Chinese patients with plaque psoriasis Trial shows guselkumab helps Chinese patients with plaque psoriasis
This Phase 4 randomized controlled trial of 327 Chinese patients with moderate-to-severe plaque psoriasis found guselkumab significantly sup…
A new trial shows that guselkumab significantly improves skin clarity for Chinese patients living with moderate to severe plaque psoriasis.
Sep 5, 2026
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis
Dermatology RCT
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis Trial shows BAT2306 performs similarly to secukinumab for plaque psoriasis
This Phase 3 randomized controlled trial evaluated 502 adults with moderate-to-severe plaque-type psoriasis. The study found that BAT2306 de…
A new clinical trial shows that the medication BAT2306 offers similar results and safety for plaque psoriasis compared to the established dr…
Sep 1, 2026
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
Oncology Meta-analysis
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
Frontiers Jul 26, 2026
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles
Rheumatology Meta-analysis
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles Plant compounds combined with standard care improve psoriasis symptoms
This systematic review and network meta-analysis of 84 randomized controlled trials involving 7,544 patients found that combination therapie…
Combining specific plant-derived ingredients with standard treatments may offer better results for people living with psoriasis.
Frontiers Jun 22, 2026
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
Dermatology Phase III
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Frontiers Jun 10, 2026
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Dermatology Meta-analysis
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Jun 1, 2026
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Dermatology RCT
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
Jun 1, 2026
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
Dermatology FDA Approval
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older The FDA has approved a new drug called Cosentyx for treating a serious skin condition
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older.
FDA Apr 22, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Apr 21, 2026

Research across Psoriasis

Related studies from across the Psoriasis family.

Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups
Neurology Sys. Review
Autoimmune comorbidities recur with MS, but evidence cannot define a prodrome or distinct subgroups Common autoimmune conditions often occur alongside multiple sclerosis
This scoping review synthesizes evidence on immune-mediated comorbidities in multiple sclerosis. Autoimmune thyroid disease, type 1 diabetes…
People with multiple sclerosis often have other autoimmune conditions like thyroid disease or psoriasis, but the link to disease progression…
Frontiers Oct 29, 2026
Telitacicept Shows Satisfactory Response in Complex Overlap Syndrome Case
Neurology Guideline
Telitacicept Shows Satisfactory Response in Complex Overlap Syndrome Case Telitacicept Shows Potential in Rare Overlap Syndrome Case
This is a single case report describing a patient with systemic lupus erythematosus, immune-mediated necrotizing myopathy, Sjögren's syndrom…
A single case report describes a patient with four autoimmune conditions who responded well to a regimen containing telitacicept.
Frontiers Oct 18, 2026
Vigorous activity and regular exercise are associated with lower psoriasis prevalence in patients with psoriasis
Allergy & Immunology Meta-analysis
Vigorous activity and regular exercise are associated with lower psoriasis prevalence in patients with psoriasis Regular Exercise May Help Manage Psoriasis and Joint Pain
This umbrella review synthesizes evidence on exercise, physical activity, and fitness for patients with psoriasis and psoriatic arthritis. T…
Regular physical activity and vigorous exercise may be linked to lower psoriasis prevalence and improved symptoms for those with psoriatic a…
Frontiers Oct 10, 2026
Inflammatory memory mechanisms may drive chronic relapse and offer pathways for disease modification in rosacea
Dermatology Sys. Review
Inflammatory memory mechanisms may drive chronic relapse and offer pathways for disease modification in rosacea New framework explores why rosacea and psoriasis keep returning
This hypothesis-generating critical review explores inflammatory memory, including epigenetic memory and trained immunity, as a framework fo…
Scientists are looking into how the body remembers inflammation, which could help explain why skin conditions like rosacea often flare up re…
Frontiers Oct 1, 2026
Keratinocytes drive psoriasis inflammation through bidirectional epithelial-immune crosstalk
Dermatology Sys. Review
Keratinocytes drive psoriasis inflammation through bidirectional epithelial-immune crosstalk Skin cells play a key role in driving psoriasis inflammation
This narrative review synthesizes evidence that keratinocytes are active participants in a bidirectional epithelial-immune network driving p…
New research shows that skin cells are not just passive victims of psoriasis but active participants in driving the cycle of inflammation.
Frontiers Sep 29, 2026
IRF4 acts as a context-encoded mediator in immune compartments and skin repair processes
Dermatology Sys. Review
IRF4 acts as a context-encoded mediator in immune compartments and skin repair processes Understanding the Role of IRF4 in Treating Skin Inflammation Conditions
This narrative review examines the role of Interferon regulatory factor 4 (IRF4) in immune compartments and skin conditions. The review iden…
Scientists are looking at how the IRF4 protein affects skin diseases like psoriasis and eczema to find better ways to manage symptoms.
Frontiers Sep 22, 2026
Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment
Dermatology Sys. Review
Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment New Research Identifies Nervous System Links in Psoriasis Treatment
This systematic review examines the interactions between multiple cellular components and the nervous system in psoriasis. The review aims t…
New research explores how the nervous system interacts with skin cells in psoriasis to help identify new ways to treat the condition.
Frontiers Sep 10, 2026
Ustekinumab May Improve Inverse Psoriasis in Single Case Report
Dermatology Guideline
Ustekinumab May Improve Inverse Psoriasis in Single Case Report Ustekinumab Shows Promise for Treatment of Inverse Psoriasis
This is a single case report of a 32-year-old male with inverse psoriasis treated with four subcutaneous ustekinumab injections. Skin lesion…
A new case report shows how a specific medication, ustekinumab, significantly improved skin lesions and itching for a patient with inverse p…
Frontiers Sep 10, 2026
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis
Allergy & Immunology Sys. Review
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis Vunakizumab Linked to Severe Ulcerative Colitis in Single Case
This case report and literature review describes a single case of severe ulcerative colitis and hepatic enzyme elevation following vunakizum…
A single case report shows a patient developed severe ulcerative colitis and high liver enzymes after receiving vunakizumab injections.
Frontiers Sep 4, 2026
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients
Dermatology Meta-analysis
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients Factors Like Age and BMI Impact Psoriasis Treatment Success
This meta-analysis of 13,902 patients evaluates predictors of clinical response to biologic therapies in psoriasis. The analysis identifies …
New data shows that age, body mass index, and other health factors can influence how well patients with psoriasis respond to biologic therap…
Sep 1, 2026
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles
Drug Pipeline Sys. Review
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles IL-17 blockers show promise for autoimmune diseases
This systematic review examines IL-17 axis targeting with monoclonal antibodies and small-molecule inhibitors across psoriasis, lupus, perio…
New review finds IL-17-targeting drugs work well for psoriasis and other conditions, but cost and side effects remain hurdles.
Frontiers Aug 23, 2026
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets
Genetics & Precision Medicine Meta-analysis
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets 78 proteins linked to psoriasis may reveal new drug targets
This meta-analysis of genome-wide association studies (GWAS) identified 78 circulating proteins with genetically predicted associations with…
A large genetic study found 78 proteins tied to psoriasis, including 12 promising drug targets. This could lead to new treatments.
medRxiv Aug 22, 2026

Questions about Plaque psoriasis

How does bimekizumab compare to placebo for treating moderate to severe chronic plaque psoriasis?

Bimekizumab is significantly more effective than placebo for clearing skin in moderate to severe chronic plaque psoriasis, with Phase 3 trials showing high response rates at week 16.

Full answer →
Can Stelara be used to treat plaque psoriasis in pediatric patients 6 years and older?

Yes, Stelara (ustekinumab) is FDA-approved for treating moderate to severe plaque psoriasis in pediatric patients 6 years and older.

Full answer →
Is Cosentyx approved for adults with moderate to severe plaque psoriasis?

Yes, Cosentyx (secukinumab) is FDA-approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Full answer →
Are biologic drugs better than placebo for treating plaque psoriasis in children?

Yes, biologic drugs are significantly more effective than placebo for treating moderate to severe plaque psoriasis in children aged 6 years and older, based on multiple clinical trials and meta-analyses.

Full answer →

All Plaque psoriasis Articles